Question

Стойна ли е терапията със стволови клетки за Болест на Паркинсон?

Outside trials, evidence does not support it. Unproven therapy carries surgical and immune risks and yields modest, temporary change at best. Established medications are proven, adjustable and far cheaper; deep-brain stimulation, though invasive and costly, is approved with sustained benefit for selected patients. Pursue stem cells only within a formal trial, with independent supervision and realistic, research-oriented expectations.

How stem cells are studied for Parkinson's Disease

Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra. Stem-cell research pursues two complementary routes: neurogenic cells differentiated toward dopamine neurons are studied to replace lost cells and restore dopamine signalling, while placental mesenchymal stem cells are explored for neuroprotection — slowing degeneration through anti-inflammatory and growth-factor secretion. Preclinical evidence suggests dopamine-releasing cells can reinnervate the striatum and that trophic factors may delay neuronal death. Key challenges are achieving cell survival, integration and functional restoration in a degenerating brain. Most trials are early-phase, with modest motor changes reported.

Съм ли кандидат? → · Parkinson's Disease: full overview → · Цена Болест на Паркинсон → · Cost →

Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.

Клетъчна терапия на европейско ниво — без европейските цени.

GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.

Безплатна медицинска оценка